Clinical trial · Interventional
A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC
Phase II Trial of Exploring the Predictive Factors of Docetaxol Plus Capecitabine(TX) Regimen and Oxaliplatin Plus Capecitabine (XELOX) Regimen in the First Line Treatment of Patients With Metastatic Gastric Cancer (MGC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Platinum, fluorouracil and taxane based regimen are all acceptable in the first line treatment of metastatic gastric cancer. The TX and XELOX regimen are two common regimen used in MGC. whichever regimen is used, the average response rate is less than 50%. So a rather part of patients can't get benefit from the treatment. It is urgent to find out the predictive factors of these regimens in order to get a higher response and better survival outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Capecitabine | Drug | Capecitabine | ALIAS |
| Docetaxol | Drug | — | UNRESOLVED |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Docetaxol ＆Capecitabine (TX)
- description
- Docetaxol: 75 mg/m2 d1, (From MAY 15th 2013, the dose was reduced to 60mg/m2 for high incidence of G3/4 myelosuppression after approved by institute Ethics Committee) ; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
- interventionNames
- Drug: Docetaxol
- Drug: Capecitabine
- type
- ACTIVE_COMPARATOR
- label
- Oxaliplatin ＆Capecitabine (XELOX)
- description
- Oxaliplatin: 130 mg/m2 d1; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
- interventionNames
- Drug: Oxaliplatin
- Drug: Capecitabine
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Chemo-naive patients with metastatic, unresectable, histologically confirmed gastric or Gastroesophageal adenocarcinoma; Patients who received adjuvant chemotherapy, the duration from the last therapy to relapse at least longer than 6 months * Patient must have at least one measurable lesions (RECIST 1.1) * 18 Years to 75 years * Written informed consent obtained * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Patients must have adequate organ and marrow function as defined below: * neutrophilicgranulocyte greater than/equal to 1,500/mm3; * platelets greater than/equal to 90,000/ mm3; * hemoglobin greater than/equal to 9 gm/dL (may be transfused to maintain or exceed this level); * total bilirubin less than/equal to 1.5 within institutional upper limit of normal (IULN); * Aspartate Transaminase (AST,SGOT)/Alanine transaminase (ALT,SGPT) less than/equal to 2.5 times IULN * serum creatinine less than/equal to 1.5 x IULN. Exclusion Criteria: * Active clinically serious infections (\> grade 2 NCI-CTC version 3.0, National Cancer Institute-Common Terminology Criteria for Adverse Events) * Symptomatic metastatic brain or meningeal tumors * History of organ allograft * Patients undergoing renal dialysis * chronic inflammatory bowel disease; ileus; genetic fructose intolerance * Patients who received adjuvant chemotherapy and the duration from the last therapy less than 6 months * Receive previously radiotherapy in measurable regions * Pregnancy or lactating status * Concurrent malignancy other than nonmelanoma skin cancer, or in situ cervix carcinoma * Clinically relevant coronary artery disease or history of a myocardial infarction within the last 12 months * Acute or subacute intestinal occlusion or history of the inflammatory bowel disease * Any factors that influence the usage of oral administration
References
Publications (0)
Data not yet available